GLP-1 weight loss plateaus: what the science says about the 'hidden' phase

What did @theol9070 actually say?

Nothing about GLP-1s. Not a single word. The transcript is entirely song lyrics, something along the lines of "you're the light that guides me home" and "I'm looking at the nice guy." Whatever the caption promised about Ozempic plateaus and appetite crashes, the video itself delivered a ballad. There are no verifiable claims to fact-check because no health claims were actually made on camera.

The caption teases a narrative arc that a lot of GLP-1 users will recognize: fast early results, followed by something that "catches people off guard." That framing, combined with hashtags like #mounjarouk and #glp1community, signals to a specific audience that health information is coming. It isn't. The video is either a lip-sync, a music overlay, or a partially uploaded clip where the actual commentary never made it into the transcript.

Does the science back this up?

There is no claim here to evaluate against the literature. But the caption's implied premise, that GLP-1 users experience a honeymoon phase followed by a harder stretch, is actually well-supported. So let's engage with that idea, since it's clearly what this creator intended to discuss.

Early weight loss on semaglutide is real and measurable. In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), participants lost roughly 6% of body weight in the first 12 weeks, with the steepest trajectory early on. Appetite suppression is strongest in the initial titration period. What follows, for many people, is a slower loss phase that can feel like the drug has stopped working. It hasn't, necessarily. The body is adapting. Lean mass loss, reduced resting metabolic rate, and hormonal adaptation all contribute to the plateau effect documented in longer follow-up data from the SUSTAIN and STEP trial extensions.

What did they get wrong (or right)?

The creator got nothing wrong about GLP-1s because they said nothing about GLP-1s. That's the whole problem. The caption sets up a legitimate and genuinely useful conversation about what happens after the initial weight loss phase, and then the video doesn't deliver it. That's a credibility issue, not a medical accuracy issue.

What's worth noting: the implied story in the caption is broadly accurate. Early enthusiasm followed by a plateau is one of the most common experiences reported in GLP-1 forums and in clinical dropout data. A 2023 analysis by Kushner et al. in Obesity Reviews found that patient expectations around continued rapid loss were a significant driver of early discontinuation. People expect the first-month results to continue indefinitely. They don't. If this creator was building toward that point, it's a genuinely worthwhile one. It just never arrived in the transcript.

What should you actually know?

If you're on semaglutide or tirzepatide and the scale has slowed down, that doesn't mean the medication has failed. Weight loss on GLP-1 receptor agonists is not linear. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide's maximum effect was still accumulating at 72 weeks for many participants. The early weeks are not the whole story.

A few things worth understanding:

• Appetite suppression tends to be most dramatic during the titration phase. As your body adjusts to a maintenance dose, hunger signals may partially return. This is normal and documented.
• Muscle mass loss is a real concern on aggressive calorie restriction combined with GLP-1 therapy. Resistance training and adequate protein intake are consistently recommended in clinical practice guidelines, though this is a conversation to have with your prescriber.
• Plateaus at 12 to 16 weeks are common and do not necessarily indicate treatment failure. A 2022 paper by Blundell et al. in Diabetes, Obesity and Metabolism described this as physiological adaptation, not medication ineffectiveness.
• Compounded semaglutide is not the same as brand-name Ozempic or Wegovy. Formulation, excipients, and quality controls differ. This matters clinically.

The caption on this video gestures at something real. The video itself doesn't get there. If you're looking for honest information about the harder parts of the GLP-1 journey, look for creators who actually say the thing out loud, on camera.